Jakub Porzycki|Nurphoto|Getty Images
Novo Nordisk on Wednesday reported a third-quarter beat for sale of its hit weight-loss medication Wegovy and tightened its 2024 full-year development support.
Company shares leapt beforehand Wednesday and were last up 7.7% at 9:02 a.m. London time.
The Danish pharmaceutical titan stated that its web revenue in the 3rd quarter struck 27.3 billion Danish kroner ($ 3.92 billion), over an LSEG accumulated quote of 26.95 billion Danish kroner.
Novo Nordisk included that sales of Wegovy were 79% greater year-on-year in the 3rd quarter, being available in at 17.3 billion Danish kroner. This was over the 15.9 billion Danish kroner expert had actually been anticipating according to a company-compiled agreement, Reuters reported.
The firm tightened its sales development expectation for the complete year 2024 to 23% to 27% from 22% to 28% at continuous currency exchange rate and tightened its operating revenue development support to find in at 21% to 27%, versus the formerly anticipated 20% to 28%, both at continuous currency exchange rate.
The support mirrored the firm’s assumptions offer for sale development in North America and worldwide, which is mainly driven by quantity development of therapies based upon Glucagon- like peptide-1 (GLP-1), Novo Nordisk stated.
“Following higher-than-expected volume growth in recent years, including GLP-1-based products such as Ozempic and Wegovy, combined with the expectation of continued volume growth and capacity limitations at some manufacturing sites, the outlook also reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies,” it included.
Novo Nordisk included that it was buying capability both inside and on the surface to enhance supply in the brief- and lasting.
Regionally, Novo Nordisk’s sales raised 22% in North America in the 3rd quarter of 2024 contrasted to a year previously. Sales to the crucial united state market were up 21% over the duration, with GLP-1 quantity development up 15% in the area.
“Novo Nordisk is the market leader with 53.9% measured by total monthly prescriptions and 50.0% measured by new-to-brand prescriptions,” the firm stated.
The health care titan has actually weathered significantly solid competitors, however likewise got encouraging information in the weight-loss room in current months.
Last week, the united state Food and Drug Administration stated all dosages of Wegovy were currently offered in the united state after formerly keeping in mind that the most affordable dosage of Wegovy remained in brief supply. The information was taken as a signal that Novo Nordisk’s initiatives to increase products of Wegovy and diabetes mellitus medication Ozempic are settling.
Also in October, a research study revealed that Ozempic might minimize the danger of establishing Alzheimer’s condition, recommending its possible to postpone or stop the memory-robbing problem.
–‘s Annika Kim Constantino added to this tale
